The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany
- PMID: 33016109
- DOI: 10.2217/cer-2020-0131
The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany
Abstract
In this study, we assessed the productivity gains associated with the use of obinutuzumab in combination with chemoimmunotherapy (G-chemo) in first-line treatment among follicular lymphoma patients. Health benefits, measured as an increase in progression-free survival, were translated into productivity gains in both paid and unpaid work using gross value added as productivity measure. From 2017 to 2030, 11,870 overall progression-free years can be gained by utilizing obinutuzumab. These progression-free years correspond to undiscounted productivity gains of about €187.9 million in paid work and about €535.9 million in unpaid work. Our study shows that the benefits of the use of obinutuzumab in the first-line treatment of follicular lymphoma extend beyond clinical advantages.
Keywords: economic evaluation; follicular lymphoma; productivity; societal value.
Similar articles
-
First-line obinutuzumab for follicular lymphoma.Lancet Oncol. 2017 Nov;18(11):e648. doi: 10.1016/S1470-2045(17)30781-7. Epub 2017 Oct 13. Lancet Oncol. 2017. PMID: 29033196 No abstract available.
-
Management of patients with follicular lymphoma treated first line with obinutuzumab.Asia Pac J Clin Oncol. 2019 May;15 Suppl 3:3-11. doi: 10.1111/ajco.13153. Asia Pac J Clin Oncol. 2019. PMID: 31058467
-
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8. Lancet Haematol. 2019. PMID: 31296423 Clinical Trial.
-
The role of obinutuzumab in the management of follicular lymphoma.Future Oncol. 2019 Nov;15(31):3565-3578. doi: 10.2217/fon-2019-0193. Epub 2019 Sep 20. Future Oncol. 2019. PMID: 31538821 Review.
-
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):508-518.e14. doi: 10.1016/j.clml.2018.05.009. Epub 2018 May 23. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29934061 Review.
Cited by
-
Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis.Clinicoecon Outcomes Res. 2021 Jul 22;13:661-671. doi: 10.2147/CEOR.S317885. eCollection 2021. Clinicoecon Outcomes Res. 2021. PMID: 34321898 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
